Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study of the Impact of RoActemra/Actemra on Fatigue in Patients With Rheumatoid Arthritis (PEPS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/= 18 years of age~* Moderate to severe rheumatoid arthritis~* Inadequate response to disease-modifying antirheumatic drugs (DMARDS) or anti-TNF (tumor necrosis factor) drugs~Exclusion Criteria:~* Hypersensitivity to RoActemra/Actemra or any component~* Active infection~* Participation in a clinical trial in rheumatoid arthritis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab (Type: None): Eligible participants receiving tocilizumab according to summary of product characteristics in a real life setting will be observed for 4 months

Based on this trial design, predict the completion outcome and termination type (if applicable).